Bristol Myers Squibb News

In addition to Bristol-Myers Squibb, the II-ON is currently comprised of ten leading cancer-research institutions, including: An objective of this collaborative forum is to facilitate the translation of scientific research findings into clinical trials and, eventually, clinical practice.

For years, doctors had little to offer people with advanced melanoma skin cancer - cases diagnosed after the cancer has spread.

Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019 http://www.reportlinker.com/p0869191/Hepatitis-B-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy GlobalData, the industry analysis specialist, has released its new report, "Hepatitis B ... (more)

Teva Pharmaceuticals Industries Ltd. fell for a fourth week in New York, its longest losing streak since November, as the Israeli drug maker's guidance cut spurred Piper Jaffray & Co.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

Having a disciplined approach to creating a functional dividend portfolio often comes with the need to stringently diversify.

America is sticking people in prison like it's a frivolous contest when instead the numbers add up to a great cruelty that achieves minimal good.

Amylin Pharmaceuticals Inc. , the diabetes drugmaker that's up for sale, has received first-round bids from Sanofi and Merck & Co.

CRANBURY, N.J., May 25, 2012 /PRNewswire/ -- Oncobiologics, Inc. announced today that it has filled two important leadership positions with established biopharmaceutical industry experts.

Lamberto Andreotti , chief executive officer, will answer questions about the company at 9 a.m. EST.

Are you looking for large-cap companies that still have room to grow? In search of attractive dividend stocks? Do you prefer investing in stocks that analysts have weighed in on? Do you prefer companies with strong profits? For ideas on where to look, we ran a screen you may be interested in.

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.

BUYINS.NET: Market Maker Surveillance Report. MS, T, JPM, BMY, GWBU, FB, Highest Net Sell Volume and Negative Price Friction For Monday, May 21st 2012 May 22, 2012 -- BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday.

Editor's Note: The following is a news release issued by the Mercer County chapter of the National Alliance on Mental Illness.

There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve.

We like companies that have little or no debt, because these companies tend to have long-term competitive advantage.

The popular blood thinner Plavix is going generic, the Food and Drug Administration said Thursday, giving lower cost options for the people who take the blood thinner to reduce their risk for stroke and heart attack.

Shares of Bristol Myers Squibb opened at 32.75 on Friday. Bristol Myers Squibb has a 52 week low of $25.69 and a 52 week high of $35.44. The company has a market cap of $55.318 billion and a P/E ratio of 14.69. Bristol Myers Squibb last announced its earnings results on Thursday, April 26th.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia May 16, 2012 -- Announcing two separate strategic China initiatives yesterday, Bristol-Myers Squibb increased its commitment to building its presence in China and its bid for ... (more)

NEW YORK &#8212 Shares of some top pharmaceuticals companies are mixed at 1 p.m.: Baxter International Inc.